---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-25-000078"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:33:54.375248+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics raises $11.3M, extends cash runway to H2 2026; Q2 net loss narrows to $2.5M

## Summary
- Net proceeds of ~$10.1M from two public offerings and ATM; cash runway now into H2 2026.
- Q2 2025 net loss $2.5M vs $5.0M in Q2 2024; R&D expense fell to $1.5M from $3.6M.
- INVINCIBLE-3 (soft tissue sarcoma) enrollment paused in March after 23 patients; existing patients continue dosing.
- INVINCIBLE-4 (triple-negative breast cancer) recruiting in France and Switzerland; EMA authorized initiation.
- INT230-6 showed 100% complete response in preclinical MPNST models; company believes Nasdaq compliance restored.

## SEC filing metadata
- accession: 0001567264-25-000078
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000078/0001567264-25-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000078/intensity-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-25-000078
- JSON: https://secwatch.observer/filing/0001567264-25-000078.json
- Plain text: https://secwatch.observer/filing/0001567264-25-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.